First Horizon Advisors, Inc. Editas Medicine, Inc. Transaction History

First Horizon Advisors, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$8.32 - $13.21 $2,021 - $3,210	-243 Reduced 51.37%	230 $2,000
Q3 2022 Nov 09, 2022	SELL	$12.16 - $19.42 $97 - $155	-8 Reduced 1.66%	473 $5,000
Q2 2022 Aug 02, 2022	BUY	$9.99 - $21.35 $4,805 - $10,269	481 New	481 $5,000
Q1 2022 May 10, 2022	SELL	$14.08 - $27.63 $10,771 - $21,136	-765 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$26.55 - $40.57 $11,363 - $17,363	-428 Reduced 35.88%	765 $20,000
Q3 2021 Nov 15, 2021	SELL	$39.27 - $72.94 $212,647 - $394,970	-5,415 Reduced 81.95%	1,193 $49,000
Q3 2021 Nov 09, 2021	BUY	$39.27 - $72.94 $229,729 - $426,699	5,850 Added 771.77%	6,608 $271,000
Q2 2021 Aug 09, 2021	BUY	$31.29 - $56.64 $8,417 - $15,236	269 Added 55.01%	758 $42,000
Q1 2021 May 11, 2021	BUY	$39.71 - $90.58 $19,418 - $44,293	489 New	489 $20,000
Q3 2020 Nov 12, 2020	SELL	$28.06 - $37.16 $15,433 - $20,437	-550 Closed	0 $0
Q4 2019 Jan 07, 2020	BUY	$19.49 - $32.63 $10,719 - $17,946	550 New	550 $16,000

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on First Horizon Advisors, Inc. with notifications on news.